Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy.

The absence of dystrophin at the muscle membrane leads to Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease that is inevitably fatal in early adulthood. In contrast, dystrophin-deficient mdx mice appear physically normal despite their underlying muscle pathology. We describe mice deficient for both dystrophin and the dystrophin-related protein utrophin. These mice show many signs typical of DMD in humans: they show severe progressive muscular dystrophy that results in premature death, they have ultrastructural neuromuscular and myotendinous junction abnormalities, and they aberrantly coexpress myosin heavy chain isoforms within a fiber. The data suggest that utrophin and dystrophin have complementing roles in normal functional or developmental pathways in muscle. Detailed study of these mice should provide novel insights into the pathogenesis of DMD and provide an improved model for rapid evaluation of gene therapy strategies.

• Publication year

  1997

• Venue

  Cell

• Publication date

  1997-08-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0092-8674(00)80532-2PMID 9288751
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ultrastructure of the skeletal muscle in the X chromosome-linked dystrophic (mdx) mouse

  2004cited by this paper
• Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy.

  1997cited by this paper
• Postsynaptic Abnormalities at the Neuromuscular Junctions of Utrophin-deficient Mice

  1997influential reference
• Subtle Neuromuscular Defects in Utrophin-deficient Mice

  1997cited by this paper
• Genes at the junction--candidates for congenital myasthenic syndromes.

  1997cited by this paper
• MyoD is required for myogenic stem cell function in adult skeletal muscle.

  1996cited by this paper
• The mdx‐amplification‐resistant mutation system assay, a simple and rapid polymerase chain reaction‐based detection of the mdx allele

  1996cited by this paper
• The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo.

  1996cited by this paper
• Morphology of diaphragm neuromuscular junctions on different fibre types

  1996cited by this paper
• Utrophin: A Structural and Functional Comparison to Dystrophin

  1996cited by this paper
• Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene

  1996cited by this paper
• MyoD is required for myogenic stem cell function in adult skeletal muscle

  1996cited by this paper
• Dystrophin-associated proteins in muscular dystrophy.

  1995cited by this paper
• Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury.

  1995cited by this paper
• Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex.

  1995cited by this paper
• Utrophin actin binding domain: analysis of actin binding and cellular targeting.

  1995cited by this paper
• Site and mechanics of failure in normal and dystrophin‐deficient skeletal muscle

  1995cited by this paper
• Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage.

  1995cited by this paper
• Profiles of neuromuscular diseases. Becker's muscular dystrophy.

  1995cited by this paper
• Does utrophin expression in muscles of mdx mice during postnatal development functionally compensate for dystrophin deficiency?

  1994cited by this paper
• Expression of dystrophin-associated glycoproteins and utrophin in carriers of Duchenne muscular dystrophy.

  1994cited by this paper
• Increasing complexity of the dystrophin-associated protein complex.

  1994cited by this paper
• beta 2-Syntrophin: localization at the neuromuscular junction in skeletal muscle.

  1994cited by this paper
• Talin, vinculin and DRP (utrophin) concentrations are increased at mdx myotendinous junctions following onset of necrosis.

  1994cited by this paper
• Myosin isoforms in mammalian skeletal muscle.

  1994cited by this paper
• Utrophin Localization in Normal and Dystrophin‐Deficient Heart

  1994cited by this paper
• New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin

  1993cited by this paper
• Localization and Quantitation of the Chromosome 6-Encoded Dystrophin-Related Protein in Normal and Pathological Human Muscle

  1993cited by this paper
• Evidence for myoblast-extrinsic regulation of slow myosin heavy chain expression during muscle fiber formation in embryonic development

  1993cited by this paper
• Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle

  1993cited by this paper
• The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies.

  1992cited by this paper
• Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle

  1992cited by this paper
• Different distributions of dystrophin and related proteins at nerve-muscle junctions.

  1992cited by this paper
• Localization of dystrophin relative to acetylcholine receptor domains in electric tissue and adult and cultured skeletal muscle

  1991cited by this paper
• Expression of myosin heavy chain isoforms in Duchenne muscular dystrophy patients and carriers.

  1991cited by this paper
• Structure and function of the neuromuscular junction in young adultmdx mice

  1991cited by this paper
• Neuromuscular transmission in the mdx mouse

  1990cited by this paper
• Distribution of Na+ channels and ankyrin in neuromuscular junctions is complementary to that of acetylcholine receptors and the 43 kd protein.

  1989cited by this paper
• The molecular basis of muscular dystrophy in the mdx mouse: a point mutation.

  1989cited by this paper
• Three myosin heavy chain isoforms in type 2 skeletal muscle fibres

  1989cited by this paper
• The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates.

  1987cited by this paper
• X chromosome-linked muscular dystrophy (mdx) in the mouse.

  1984cited by this paper
• Development, innervation, and activity-pattern induced changes in skeletal muscle.

  1981cited by this paper
• Muscle disorders in childhood.

  1977cited by this paper
• Duchenne dystrophy. II. Morphometric study of motor end-plate fine structure.

  1974cited by this paper
• Neural regulation of enzymes in muscle fibers of red and white muscle.

  1967cited by this paper

• RNA-Based Therapies for Treating Monogenic Cardiomyopathies.

  2026cites this paper
• Functional and structural pathologies in skeletal muscle of a rat model of Duchenne muscular dystrophy.

  2026cites this paper
• Engineered muscle tissues with enhanced maturation enable the identification of clinically relevant rAAV capsids

  2026cites this paper
• Cardiac and skeletal muscle delivery of biotherapeutics with a blood vessel epicardial substance-targeting peptide.

  2026cites this paper
• Intercellular communication from myotubes to fibroblasts is differentially impacted by mineralocorticoid receptor signaling and muscular dystrophy

  2025cites this paper
• DRP2 promotes EMT and serves as a potential therapeutic target for LUAD treatment

  2025cites this paper
• Long-Term Dystrophin Replacement Therapy in Duchenne Muscular Dystrophy Causes Cardiac Inflammation

  2025cites this paper
• Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging Therapies

  2025cites this paper
• CTLA4-Ig reduces muscle fiber damage in a model of Duchenne muscular dystrophy by attenuating pro-inflammatory gene expression in myeloid lineage cells.

  2025cites this paper
• Functional and structural pathologies in skeletal muscle of a rat model of Duchenne muscular dystrophy

  2025cites this paper
• Respiratory pathology in the mdx/utrn -/- mouse: A murine model for Duchenne Muscular Dystrophy (DMD)

  2025influential citation
• Targeting Skeletal Muscle in Duchenne Muscular Dystrophy: Integrating In-Silico and Experimental Approaches to SGLT2 Inhibition.

  2025cites this paper
• Transcriptional adaptation upregulates utrophin in Duchenne muscular dystrophy

  2025cites this paper
• Multi‐Parametric Quantitative MRI in the Early Differential Diagnosis of Ambulatory Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

  2025cites this paper
• Growth Hormone Secretagogue Receptor (GHSR) Is Elevated in Myocardial Tissues of DMD mdx:utrn−/− Mice, and Correlates Strongly with Inflammatory Markers, and Negatively with Cardiac Function

  2025cites this paper
• Transcriptional adaptation: where mRNA decay meets genetic compensation.

  2025cites this paper
• Genetic strategies for therapy of Duchenne muscular dystrophy

  2025cites this paper
• Exploring new therapeutics for Duchenne muscular dystrophy and related cardiomyopathy

  2025cites this paper
• Cardiac Cell and Animal Models for Duchenne Muscular Dystrophy in the Era of Gene Therapy and Precision Medicine

  2025cites this paper
• Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy

  2024cites this paper
• Antisense oligonucleotides and their applications in rare neurological diseases

  2024cites this paper
• Glycative stress inhibits hypertrophy and impairs cell membrane integrity in overloaded mouse skeletal muscle

  2024cites this paper
• Two Novel Mouse Models of Duchenne Muscular Dystrophy with Similar Dmd Exon 51 Frameshift Mutations and Varied Phenotype Severity

  2024cites this paper
• Respiratory performance in Duchenne muscular dystrophy: Clinical manifestations and lessons from animal models

  2024cites this paper
• Profound cellular defects attribute to muscular pathogenesis in the rhesus monkey model of Duchenne muscular dystrophy.

  2024cites this paper
• Gene therapy delivered micro-dystrophins co-localize with transgenic utrophin in dystrophic skeletal muscle fibers.

  2024cites this paper
• The BALB/c.mdx62 mouse exhibits a dystrophic muscle pathology and is a model of Duchenne muscular dystrophy

  2024cites this paper
• Pannexin 1 dysregulation in Duchenne muscular dystrophy and its exacerbation of dystrophic features in mdx mice

  2024cites this paper
• Myosin Va: Capturing cAMP for synaptic plasticity

  2024cites this paper
• Upregulation of utrophin improves the phenotype of Duchenne muscular dystrophy hiPSC-derived CMs

  2024cites this paper
• H3K27ac modification and transcription characteristics of adipose and muscle tissues in Chuxiang Black pig.

  2024cites this paper
• Molecular pathways involved in the control of contractile and metabolic properties of skeletal muscle fibers as potential therapeutic targets for Duchenne muscular dystrophy

  2024cites this paper
• In vivo shear wave elasticity imaging for assessment of diaphragm function in muscular dystrophy.

  2023cites this paper
• NMJ-related diseases beyond the congenital myasthenic syndromes

  2023cites this paper
• T cell biology in neuromuscular disorders: a focus on Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis

  2023cites this paper
• Humanization of the mdx Mouse Phenotype for Duchenne Muscular Dystrophy Modeling: A Metabolic Perspective

  2023cites this paper
• Utrophin correlates with disease severity in Duchenne muscular dystrophy.

  2023cites this paper
• Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies

  2023cites this paper
• Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy model

  2023cites this paper
• Keeping your strength up: induced pluripotent stem cell-based approaches for the treatment and investigation of skeletal muscle disorders

  2023cites this paper
• Transcriptomic analysis of paired healthy human skeletal muscles to identify modulators of disease severity in DMD

  2023cites this paper
• Duchenne muscular dystrophy: disease mechanism and therapeutic strategies

  2023cites this paper
• Therapeutic approaches for Duchenne muscular dystrophy

  2023cites this paper
• Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies

  2023cites this paper
• Increasing muscle contractility through low-frequency stimulation alters tibial bone geometry and reduces bone strength in mdx and dko dystrophic mice.

  2023cites this paper
• Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophin.

  2023cites this paper
• Urinary titin is not an early biomarker of skeletal muscle atrophy induced by muscle denervation in mice

  2023cites this paper
• GSK3 inhibition improves skeletal muscle function and whole-body metabolism in the severe DBA/2J mdx mouse model

  2022cites this paper
• Post-synaptic specialization of the neuromuscular junction: junctional folds formation, function, and disorders

  2022cites this paper
• Proteins implicated in muscular dystrophy and cancer are functional constituents of the centrosome

  2022cites this paper
• Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression

  2022cites this paper
• Cardio‐respiratory and phenotypic rescue of dystrophin/utrophin‐deficient mice by combination therapy

  2022cites this paper
• Cardiovascular Disease in Duchenne Muscular Dystrophy

  2022cites this paper
• Selective ablation of Nfix in macrophages attenuates muscular dystrophy by inhibiting fibro‐adipogenic progenitor‐dependent fibrosis

  2022cites this paper
• Control of backbone chemistry and chirality boost oligonucleotide splice switching activity

  2022cites this paper
• Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD

  2022cites this paper
• Matricellular Protein CCN5 Gene Transfer Ameliorates Cardiac and Skeletal Dysfunction in mdx/utrn (±) Haploinsufficient Mice by Reducing Fibrosis and Upregulating Utrophin Expression

  2022cites this paper
• Myxomavirus Serp-1 Protein Ameliorates Inflammation in a Mouse Model of Duchenne Muscular Dystrophy

  2022influential citation
• Cell-Based and Gene-Based Therapy Approaches in Neuro-orthopedic Disorders: a Literature Review

  2022cites this paper
• Treino de baixa intensidade mantem a funcionalidade e fibrose em camundongos mdx

  2022cites this paper
• Histological Methods to Assess Skeletal Muscle Degeneration and Regeneration in Duchenne Muscular Dystrophy

  2022cites this paper
• Magnetic resonance quantification of skeletal muscle lipid infiltration in a humanized mouse model of Duchenne muscular dystrophy

  2022cites this paper
• Pharmacological TRPC6 inhibition improves survival and muscle function in mice with Duchenne muscular dystrophy

  2022cites this paper
• Myofibrillar Lattice Remodeling Is a Structural Cytoskeletal Predictor of Diaphragm Muscle Weakness in a Fibrotic mdx (mdx Cmah−/−) Model

  2022cites this paper
• CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives

  2022cites this paper
• Sarco(endo)plasmic reticulum Ca2+-ATPase function is impaired in skeletal and cardiac muscles from young DBA/2J mdx mice

  2022cites this paper
• CD38‐NADase is a new major contributor to Duchenne muscular dystrophic phenotype

  2022cites this paper
• Drug development progress in duchenne muscular dystrophy

  2022cites this paper
• Macroglossia and less advanced dystrophic change in the tongue muscle of the Duchenne muscular dystrophy rat

  2022cites this paper
• Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy

  2022cites this paper
• Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy

  2021cites this paper
• Improved Bone Quality and Bone Healing of Dystrophic Mice by Parabiosis

  2021cites this paper
• Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength

  2021cites this paper
• Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy

  2021cites this paper
• Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo

  2021cites this paper
• Tissue-Engineered Skeletal Muscle Models to Study Muscle Function, Plasticity, and Disease

  2021cites this paper
• Neuromuscular Development and Disease: Learning From in vitro and in vivo Models

  2021cites this paper
• The Efficacy of Naïve versus Modified Mesenchymal Stem Cells in Improving Muscle Function in Duchenne Muscular Dystrophy: A Systematic Review

  2021influential citation
• Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model

  2021influential citation
• CRISPR technologies for the treatment of Duchenne muscular dystrophy

  2021cites this paper
• Role of molecular and metabolic defects in impaired performance of dystrophic skeletal muscles

  2021cites this paper
• Beyond Mendelian Inheritance: Genetic Buffering and Phenotype Variability

  2021influential citation
• Changes in Myonuclear Number During Postnatal Growth – Implications for AAV Gene Therapy for Muscular Dystrophy

  2021cites this paper
• Serum Antibodies to N-Glycolylneuraminic Acid Are Elevated in Duchenne Muscular Dystrophy and Correlate with Increased Disease Pathology in Cmah-/-mdx Mice.

  2021cites this paper
• Dystrophin involvement in peripheral circadian SRF signalling

  2021cites this paper
• Focus on the road to modelling cardiomyopathy in muscular dystrophy.

  2021cites this paper
• Title Dystrophin regulates peripheral circadian SRF signalling Authors

  2021cites this paper
• Signaling pathways regulating the fate of fibro/adipogenic progenitors (FAPs) in skeletal muscle regeneration and disease

  2021cites this paper
• Dystrophin regulates peripheral circadian SRF signalling

  2021cites this paper
• Ifetroban Reduces Coronary Artery Dysfunction in a Mouse Model of Duchenne Muscular Dystrophy.

  2021cites this paper
• Murine models of Duchenne muscular dystrophy: is there a best model?

  2021cites this paper
• Dystrophin insufficiency causes selective muscle injury and loss Dystrophin insufficiency causes selective muscle injury and loss of dystrophin-glycoprotein complex assembly in pig skeletal of dystrophin-glycoprotein complex assembly in pig skeletal muscle muscle

  2021cites this paper
• Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice.

  2021cites this paper
• Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies

  2021cites this paper
• Animal models for researching approaches to therapy of Duchenne muscular dystrophy

  2021cites this paper
• Selective ablation of Nfix in Macrophages preserves Muscular Dystrophy by inhibiting FAPs-dependent fibrosis

  2021cites this paper
• Empowering Muscle Stem Cells for the Treatment of Duchenne Muscular Dystrophy

  2021cites this paper
• Macrophages in Skeletal Muscle Dystrophies, An Entangled Partner

  2021cites this paper
• Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways

  2021cites this paper
• Soluble guanylate cyclase stimulation mitigates skeletal and cardiac muscle dysfunction in a mdx model of Duchenne muscular dystrophy

  2021cites this paper